Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Phagenesis

Actelion HQ Switzerland

J&J agrees $30bn deal to acquire Actelion

Swiss biotech to retain control of early-stage pipeline as J&J takes minority stake in R&D spin-out

- PMLiVE

Merck pays Vertex $230m upfront for cancer programmes

Licences four DNA damage and repair programmes with first-in-class or best-in-class potential

- PMLiVE

Ipsen buys cancer business from stripped down Merrimack

Deal includes pancreatic cancer therapy Onivyde which it hopes will gain first-line approval

FDA: Cybersecurity is an ever-present risk for medical devices

US regulator issues new guidance for manufacturers

- PMLiVE

GSK targets COPD adherence with integrated inhaler sensors

Hopes real-time patient experience data will improve clinical trial engagement

- PMLiVE

M3 expands with acquisition of Vidal Group

Grows global operations to cover Europe and Latin America

Novartis day

Novartis buys two firms in pre-Christmas shopping spree

Acquires eye disease specialist Encore Vision and NASH drug firm Conatus Pharma

Novartis building

Novartis adds oral eczema drug with Ziarco acquisition

Expands dermatology pipeline with first-in-class, Pfizer-developed treatment prospect

Actelion HQ Switzerland

J&J abandons talks with Actelion as another suitor circles

Biotech said to be holding out for a higher offer as speculation of Sanofi interest builds

- PMLiVE

Medical device regulation – a risk-based approach to compliance

Medtechs will need to invest in upgrades to individual devices as well as broader business practices

- PMLiVE

InterComm International under new management

Malcolm Allison and Ben Greeves take over the med comms agency

- PMLiVE

Valeant’s proposed sale of Salix to Takeda ‘in jeopardy’

Canadian firm now intends to grow Salix salesforce to build Xifaxan and Relistor brands

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links